Case Study: The Importance of Understanding the Patient’s Perspective

References

1. Van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017 Mar;76(3):554–561.
2. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615–1621.
3. Ugarte-Gil MF, Gamboa-Cárdenas RV, Reátegui-Sokolova C, et al. Low disease activity state/remission predicts a better health-related quality of life in systemic lupus erythematosus patients. Arthritis Care Res (Hoboken). 2019 Jun:72(8).
4. Ugarte-Gil MF, Pons-Estel GJ, Vila LM, et al. Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: Results from LUMINA (LXXIX), a multiethnic, multicentre US cohort. RMD Open. 2019 May;5(1):e000955.
5. Elera-Fitzcarrald C, Fuentes A, González LA, et al. Factors affecting quality of life in patients with systemic lupus erythematosus: Important considerations and potential interventions. Expert Rev Clin Immunol. 2018 Nov;14(11):915–931.
6. Golder V, Ooi JJY, Antony AS, et al. Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus. 2018 Mar;27(3):501–506.
7. Alarcón GS, McGwin Jr G, Brooks K, et al. Systemic lupus erythematosus in three ethnic groups. XI. Sources of discrepancy in perception of disease activity: A comparison of physician and patient visual analog scale scores. Arthritis Rheum. 2002 Aug;47(4):408–413.
8. Mehat P, Atiquzzaman M, Esdaile JM, et al. Medication nonadherence in systemic lupus erythematosus: A systematic review. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1706–1713.
9. Sun K, Eudy AM, Criscione-Schreiber LG, et al. Racial disparities in medication adherence between African American and Caucasian patients with systemic lupus erythematosus and their associated factors. ACR Open Rheumatol. 2020 Jul;2(7):430–437.
10. Du X, Chen H, Zhuang Y, et al. Medication adherence in Chinese patients with systemic lupus erythematosus. J Clin Rheumatol. 2020 Apr;26(3):94–98.
11. Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2013 Jun;27(3):329–340.
12. Chehab G, Sauer GM, Richter JG, et al. Medical adherence in patients with systemic lupus erythematosus in Germany: Predictors and reasons for non-adherence—a cross-sectional analysis of the LuLa-cohort. Lupus. 2018 Sep;27(10):1652–1660.
13. Mendoza-Pinto C, García-Carrasco M, Campos-Rivera S, et al. Medication adherence is influenced by resilience in patients with systemic lupus erythematosus. Lupus. 2021 Apr. [Epub ahead of print].
14. Julian LJ, Yelin E, Yazdany J, et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum. 2009 Feb;61(2):240–246.
15. Petri M, Perez-Gutthann S, Longenecker JC, et al. Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status. Am J Med. 1991 Oct;